A Long-Term Safety Study of ALKS 5461
A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
1 other identifier
interventional
1,485
8 countries
158
Brief Summary
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 major-depressive-disorder
Started May 2014
Longer than P75 for phase_3 major-depressive-disorder
158 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 15, 2014
CompletedFirst Posted
Study publicly available on registry
May 19, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2017
CompletedResults Posted
Study results publicly available
December 14, 2018
CompletedDecember 14, 2018
November 1, 2018
3.6 years
May 15, 2014
November 21, 2018
November 21, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of Adverse Events (AEs)
Up to 56 weeks
Study Arms (1)
ALKS 5461
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Agree to use an approved method of contraception for the duration of the study
- Have the potential to safely benefit from the administration of ALKS 5461
- Have a diagnosis of major depressive disorder (MDD)
- Additional criteria may apply
You may not qualify if:
- Have a positive test for drugs of abuse
- Currently pregnant or breastfeeding
- Have a current primary Axis-I disorder other than MDD
- Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days
- Have received electroconvulsive therapy treatment within the last 2 years, or received more than 1 course of electroconvulsive treatment during their lifetime
- Have attempted suicide within the past 2 years
- Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)
- Have had a significant blood loss or blood donation within the past 60 days
- Additional criteria may apply
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Alkermes, Inc.lead
Study Sites (158)
Alkermes Investigational Site
Birmingham, Alabama, 35226, United States
Alkermes Investigational Site
Birmingham, Alabama, 35294, United States
Alkermes Investigational Site
Tucson, Arizona, 85712, United States
Alkermes Investigational Site
Little Rock, Arkansas, 72211, United States
Alkermes Investigational Site
Bellflower, California, 90706, United States
Alkermes Investigational Site
Beverly Hills, California, 90210, United States
Alkermes Investigational Site
Carson, California, 90746, United States
Alkermes Investigational Site
Garden Grove, California, 92845, United States
Alkermes Investigational Site
Glendale, California, 91206, United States
Alkermes Investigational Site
Los Alamitos, California, 90720, United States
Alkermes Investigational Site
Los Angeles, California, 90024, United States
Alkermes Investigational Site
National City, California, 91950, United States
Alkermes Investigational Site
Oakland, California, 94612, United States
Alkermes Investigational Site
Oceanside, California, 92056, United States
Alkermes Investigational Site
Orange, California, 92868, United States
Alkermes Investigational Site
Pico Rivera, California, 90660, United States
Alkermes Investigational Site
Redlands, California, 92374, United States
Alkermes Investigational Site
San Gabriel, California, 91776, United States
Alkermes Investigational Site
Sherman Oaks, California, 91403, United States
Alkermes Investigational Site
Temecula, California, 92591, United States
Alkermes Investigational Site
Torrance, California, 90502, United States
Alkermes Investigational Site
Upland, California, 91786, United States
Alkermes Investigational Site
Colorado Springs, Colorado, 80910, United States
Alkermes Investigational Site
Denver, Colorado, 80209, United States
Alkermes Investigational Site
Hartford, Connecticut, 06106, United States
Alkermes Investigational Site
Norwich, Connecticut, 06360, United States
Alkermes Investigational Site
Bradenton, Florida, 34201, United States
Alkermes Investigational Site
Coral Springs, Florida, 33067, United States
Alkermes Investigational Site
Fort Myers, Florida, 33912, United States
Alkermes Investigational Site
Gainesville, Florida, 32607, United States
Alkermes Investigational Site
Hallandale, Florida, 33009, United States
Alkermes Investigational Site
Hialeah, Florida, 33016, United States
Alkermes Investigational Site
Jacksonville, Florida, 32256, United States
Alkermes Investigational Site
Lauderhill, Florida, 33319, United States
Alkermes Investigational Site
Maitland, Florida, 32751, United States
Alkermes Investigational Site
Melbourne, Florida, 32901, United States
Alkermes Investigational Site
North Miami, Florida, 33161, United States
Alkermes Investigational Site
Oakland Park, Florida, 33334, United States
Alkermes Investigational Site
Orlando, Florida, 32801, United States
Alkermes Investigational Site
Tampa, Florida, 33613, United States
Alkermes Investigational Site
The Villages, Florida, 32162, United States
Alkermes Investigational Site
West Palm Beach, Florida, 33407, United States
Alkermes Investigational Site
Winter Haven, Florida, 33880, United States
Alkermes Investigational Site
Alpharetta, Georgia, 30005, United States
Alkermes Investigational Site
Atlanta, Georgia, 30308, United States
Alkermes Investigational Site
Decatur, Georgia, 30030, United States
Alkermes Investigational Site
Smyrna, Georgia, 30080, United States
Alkermes Investigational Site
Chicago, Illinois, 60634, United States
Alkermes Investigational Site
Chicago, Illinois, 60640, United States
Alkermes Investigational Site
Deerfield, Illinois, 60015, United States
Alkermes Investigational Site
Hoffman Estates, Illinois, 60169, United States
Alkermes Investigational Site
Joliet, Illinois, 60435, United States
Alkermes Investigational Site
Oak Brook, Illinois, 60523, United States
Alkermes Investigational Site
Skokie, Illinois, 60076, United States
Alkermes Investigational Site
Indianapolis, Indiana, 46260, United States
Alkermes Investigational Site
Lafayette, Indiana, 47905, United States
Alkermes Investigational Site
Newburgh, Indiana, 47630, United States
Alkermes Investigational Site
Valparaiso, Indiana, 46383, United States
Alkermes Investigational Site
Edgewood, Kentucky, 41017, United States
Alkermes Investigational Site
Owensboro, Kentucky, 42301, United States
Alkermes Investigational Site
Baltimore, Maryland, 21204, United States
Alkermes Investigational Site
Baltimore, Maryland, 21208, United States
Alkermes Investigational Site
Washington D.C., Maryland, 20016, United States
Alkermes Investigational Site
Belmont, Massachusetts, 02478, United States
Alkermes Investigational Site
Brockton, Massachusetts, 02301, United States
Alkermes Investigational Site
Watertown, Massachusetts, 02472, United States
Alkermes Investigational Site
Worcester, Massachusetts, 01655, United States
Alkermes Investigational Site
Flowood, Mississippi, 39232, United States
Alkermes Investigational Site
O'Fallon, Missouri, 63368, United States
Alkermes Investigational Site
Saint Charles, Missouri, 63304, United States
Alkermes Investigational Site
St Louis, Missouri, 63109, United States
Alkermes Investigational Site
St Louis, Missouri, 63141, United States
Alkermes Investigational Site
Berlin, New Jersey, 80091, United States
Alkermes Investigational Site
Cherry Hill, New Jersey, 08002, United States
Alkermes Investigational Site
Princeton, New Jersey, 08540, United States
Alkermes Investigational Site
Albuquerque, New Mexico, 87109, United States
Alkermes Investigational Site
Brooklyn, New York, 11241, United States
Alkermes Investigational Site
Jamaica, New York, 11432, United States
Alkermes Investigational Site
Mount Kisco, New York, 10549, United States
Alkermes Investigational Site
New York, New York, 10019, United States
Alkermes Investigational Site
New York, New York, 10023, United States
Alkermes Investigational Site
New York, New York, 10029, United States
Alkermes Investigational Site
New York, New York, 10128, United States
Alkermes Investigational Site
New York, New York, 10168, United States
Alkermes Investigational Site
Staten Island, New York, 10305, United States
Alkermes Investigational Site
Staten Island, New York, 10312, United States
Alkermes Investigational Site
Charlotte, North Carolina, 28204, United States
Alkermes Investigational Site
High Point, North Carolina, 27265, United States
Alkermes Investigational Site
Beachwood, Ohio, 44122, United States
Alkermes Investigational Site
Canton, Ohio, 44718, United States
Alkermes Investigational Site
Cincinnati, Ohio, 45215, United States
Alkermes Investigational Site
Cincinnati, Ohio, 45227, United States
Alkermes Investigational Site
Dayton, Ohio, 45417, United States
Alkermes Investigational Site
Mason, Ohio, 45040, United States
Alkermes Investigational Site
Middleburg Heights, Ohio, 44130, United States
Alkermes Investigational Site
Oklahoma City, Oklahoma, 73103, United States
Alkermes Investigational Site
Oklahoma City, Oklahoma, 73112, United States
Alkermes Investigational Site
Portland, Oregon, 97210, United States
Alkermes Investigational Site
Portland, Oregon, 97214, United States
Alkermes Investigational Site
Salem, Oregon, 97301, United States
Alkermes Investigational Site
Allentown, Pennsylvania, 18104, United States
Alkermes Investigational Site
Media, Pennsylvania, 19063, United States
Alkermes Investigational Site
Philadelphia, Pennsylvania, 19104, United States
Alkermes Investigational Site
Philadelphia, Pennsylvania, 19107, United States
Alkermes Investigational Site
Lincoln, Rhode Island, 02865, United States
Alkermes Investigational Site
Charleston, South Carolina, 29407, United States
Alkermes Investigational Site
Memphis, Tennessee, 38119, United States
Alkermes Investigational Site
Austin, Texas, 78731, United States
Alkermes Investigational Site
Dallas, Texas, 75231, United States
Alkermes Investigational Site
Dallas, Texas, 75390, United States
Alkermes Investigational Site
DeSoto, Texas, 75115, United States
Alkermes Investigational Site
Houston, Texas, 77081, United States
Alkermes Investigational Site
Houston, Texas, 77098, United States
Alkermes Investigational Site
San Antonio, Texas, 78229, United States
Alkermes Investigational Site
Sugar Land, Texas, 77478, United States
Alkermes Investigational Site
Wichita Falls, Texas, 76309, United States
Alkermes Investigational Site
Clinton, Utah, 84015, United States
Alkermes Investigational Site
Woodstock, Vermont, 05091, United States
Alkermes Investigational Site
Bellevue, Washington, 98007, United States
Alkermes Investigational Site
Seattle, Washington, 98104, United States
Alkermes Investigational Site
Spokane, Washington, 99204, United States
Alkermes Investigational Site
Middleton, Wisconsin, 53562, United States
Alkermes Investigational Site
Waukesha, Wisconsin, 53188, United States
Alkermes Investigational Site
Towong, Queensland, 4066, Australia
Alkermes Investigational Site
Frankston, Victoria, 3199, Australia
Alkermes Investigational Site
Melbourne, Victoria, 3004, Australia
Alkermes Investigational Site
Burgas, 8001, Bulgaria
Alkermes Investigational Site
Kazanlak, 6100, Bulgaria
Alkermes Investigational Site
Sofia, 1113, Bulgaria
Alkermes Investigational Site
Sofia, 1431, Bulgaria
Alkermes Investigational Site
Sofia, 1632, Bulgaria
Alkermes Investigational Site
Varna, 9020, Bulgaria
Alkermes Investigational Site
Veliko Tarnovo, 5000, Bulgaria
Alkermes Investigational Site
Vratsa, 3000, Bulgaria
Alkermes Investigational Site
Penticton, British Columbia, V2A 4M4, Canada
Alkermes Investigational Site
Halifax, Nova Scotia, B3S 1L8, Canada
Alkermes Investigational Site
Gatineau, Quebec, J8T 8JL, Canada
Alkermes Investigational Site
Québec, G3K 2P8, Canada
Alkermes Investigational Site
Oranienburg, Brandenburg, 16515, Germany
Alkermes Investigational Site
Achim, 28832, Germany
Alkermes Investigational Site
Berlin, 10245, Germany
Alkermes Investigational Site
Berlin, 10365, Germany
Alkermes Investigational Site
Berlin, 10629, Germany
Alkermes Investigational Site
Ellwangen, 73479, Germany
Alkermes Investigational Site
Freiburg im Breisgau, 79104, Germany
Alkermes Investigational Site
Hanover, 30159, Germany
Alkermes Investigational Site
Mainz, 55131, Germany
Alkermes Investigational Site
Schwerin, 19053, Germany
Alkermes Investigational Site
Stralsund, 18439, Germany
Alkermes Investigational Site
Budapest, 1053, Hungary
Alkermes Investigational Site
Budapest, 1135, Hungary
Alkermes Investigational Site
Budapest, 1137, Hungary
Alkermes Investigational Site
Bialystok, 15-879, Poland
Alkermes Investigational Site
Gdansk, 80-438, Poland
Alkermes Investigational Site
Gdansk, 80-546, Poland
Alkermes Investigational Site
Gorlice, 38-300, Poland
Alkermes Investigational Site
San Juan, 00918, Puerto Rico
Alkermes Investigational Site
San Juan, 00926, Puerto Rico
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Eva Stroynowski
- Organization
- Alkermes
Study Officials
- STUDY DIRECTOR
Sanjeev Pathak, MD
Alkermes, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2014
First Posted
May 19, 2014
Study Start
May 1, 2014
Primary Completion
November 20, 2017
Study Completion
November 20, 2017
Last Updated
December 14, 2018
Results First Posted
December 14, 2018
Record last verified: 2018-11